Loading organizations...
§ Private Profile · 1050 Connecticut Ave NW, Washington, D.C., United States
Zyngenia is a technology company.
Zyngenia has raised $25.0M across 1 funding round.
Key people at Zyngenia.
Zyngenia has raised $25.0M in total across 1 funding round.
Zyngenia develops biotherapeutics, specifically multi-specific antibody-derived drugs, leveraging proprietary technology to engineer advanced therapies. These innovative drugs are primarily designed to address critical unmet needs in complex diseases such as cancer and various autoimmune disorders. The company's technical approach focuses on creating highly targeted and effective treatments that go beyond conventional antibody therapeutics.
The company was founded in 2008 by Carlos Barbas, III, Ph.D. Dr. Barbas, a distinguished scientist, established Zyngenia based on his profound insights into the development of novel antibody-derived therapeutics. His scientific expertise formed the foundational knowledge and impetus for creating a company dedicated to pushing the boundaries of biopharmaceutical innovation.
Zyngenia's therapies aim to serve patients grappling with severe conditions that lack adequate treatment options. The company's overarching vision is to continuously advance the field of biotherapeutics, bringing forward new and impactful drug candidates. This forward-looking mission centers on significantly improving patient outcomes by addressing pressing medical challenges.
Zyngenia has raised $25.0M in total across 1 funding round.
Zyngenia Inc. is a biotherapeutics company developing innovative multi-specific and multi-valent biotherapeutics called Zybodies™ to address unmet needs in inflammation and cancer treatment. The company engineers single molecular entities that interact with two or more targets using proprietary patented technology, focusing on well-validated targets in neoplasms and autoimmune disorders.[1][2][4][5] It has advanced three programs into preclinical development, achieving proof-of-concept with bi-specific and tri-specific Zybodies, including candidates like tri-specific anti-Her1/Her3 Zybody (targeting EGFR for neoplasms) and Adalimumab/anti-Ang2 Zybody (targeting Ang2 and TNF-α for inflammation), all currently in discovery or preclinical stages.[1][3]
Zyngenia serves patients with cancers and autoimmune diseases by solving challenges in traditional monoclonal antibody therapies through superior multi-target engagement, potentially offering more effective treatments.[2][5][6] Incorporated in 2008 and based in Gaithersburg, Maryland, the company maintains a pipeline emphasizing antibody drug conjugates (ADCs) and targeted inhibitors like Ang2 and EGFR antagonists.[3][5]
Zyngenia Inc. was incorporated in 2008 in Gaithersburg, Maryland, establishing itself as a biotech focused on next-generation biotherapeutics.[5] While specific founders are not detailed in available sources, the company emerged from advancements in protein engineering to create multi-specific molecules, addressing limitations of single-target therapies for complex diseases like cancer and autoimmunity.[4][5] Early pivotal moments include applying its proprietary technology to build a pipeline of Zybodies™, with preclinical proof-of-concept demonstrated in inflammation and oncology programs, advancing three candidates into development.[1]
This foundation reflects a strategic pivot toward multi-valent biotherapeutics, leveraging patented platforms to generate innovative entities like bi-specific and tri-specific formats that showed early efficacy in validated models.[1][4]
Zyngenia stands out in the biotherapeutics field through these key strengths:
Zyngenia rides the wave of multi-specific antibody therapeutics, a booming trend in biotech driven by demands for more precise, potent treatments in oncology and immunology. This timing aligns with market forces favoring biologics that overcome resistance in single-target therapies, as seen in rising investments in bispecifics and ADCs amid a projected $100B+ biologics market.[1][3] Favorable dynamics include advances in protein engineering and AI-aided design, enabling Zyngenia's patented platform to tackle hard-to-drug targets like EGFR and Ang2 combinations.[4]
The company influences the ecosystem by validating multi-valent formats in preclinical models, potentially accelerating industry shifts toward poly-specific drugs that improve efficacy and reduce side effects in inflammation and cancer.[1][2][5]
Zyngenia is poised for pipeline progression, with preclinical assets potentially entering IND stages amid surging demand for multi-specific biologics. Trends like ADC expansion and bispecific approvals (e.g., in oncology) will shape its path, bolstered by its Gaithersburg base in a biotech hub.[3][5] Influence may grow through partnerships or funding as proof-of-concept data attracts big pharma, evolving from early-stage innovator to clinical contender in addressing unmet needs with Zybodies™.[1][2] This positions Zyngenia as a watchlist player in precision biotherapeutics.
Key people at Zyngenia.
Zyngenia has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in September 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2010 | $25M Series A | — | — | Announced |
